Clinical Trial

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

Study acronym: TAGGED
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-08-27; most recent amendment 2025-02-21.
Status change: Not Yet Recruiting → Recruiting 2021-09-09
Status change: Recruiting → Not Yet Recruiting 2020-11-11
Status change: Not Yet Recruiting → Recruiting 2020-11-08
Trial Details
NCT Number NCT04535271
Lead Sponsor Sarcoma Oncology Research Center, LLC
Conditions Leiomyosarcoma
Enrollment 80 participants
Start Date 2021-09-09
Primary Completion 2028-09-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-24